The group goes after a KRAS-related target on which Boehringer recently gave up.

Patients' expression of CEACAM5 might hold the key to activity after all.

The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.

One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.

This weekend’s oncology conference will feature at least 30 different ADC projects.

ASCO is fast approaching, but in the meantime Olema will have an important readout.

One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.

Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.